Table 1.
Summary of results for SRE outcomes versus change in uNTX.
| Study | Treatment 1 (number of subjects) | Treatment 2 (number of subjects) | Log (HR) SRE (SE) |
Log (RR) SRE (SE) | uNTX group difference of log (week 13/baseline) |
uNTX group difference of log (final/baseline) |
|---|---|---|---|---|---|---|
| Amgen 2017 (Amgen, Daiichi Sankyo, Inc, n.d.) | Denosumab 120 mg SC Q4W (859) |
Zoledronate 4 mg IV Q4W (859) |
−0.0156 (0.0733) |
−0.0185 (0.0542) |
−0.17 | – |
| Berenson 2001 (Berenson et al., 2001) | Zoledronate 4 mg IV Q4W (67) |
Pamidronate 90 mg IV Q4W (73) |
NR | 0.0858 (0.2496) |
−0.3848 | – |
| Fizazi 2009 (Fizazi et al., 2009) |
Denosumab, multiple doses combined (74) | Zoledronic acid/ pamidronate IV Q4W (37) |
−0.9586 (0.6728) |
−0.6932 (0.5411) |
−1.18 | – |
| Fizazi 2011 (Fizazi et al., 2011) |
Denosumab 120 mg SC Q4W (950) | Zoledronate 4 mg IV Q4W (951) |
−0.1970 (0.0749) |
−0.1229 (0.0585) |
−0.65 | – |
| Henry 2011 (Henry et al., 2011) | Denosumab 120 mg SC Q4W (886) |
Zoledronate 4 mg IV Q4W (890) |
−0.1777 (0.0823) |
−0.1455 (0.0666) |
−0.39 | – |
| Jiang 2016 (Jiang et al., 2016) | Denosumab 120 mg SC Q4W (326) |
Zoledronate 4 mg IV Q4W (159) |
NR | −0.2480 (0.3913) |
−0.3149 | – |
| Lipton 2007 (Lipton et al., 2007a) |
Denosumab, multiple doses combined (212) | Zoledronic acid/pamidronate/ ibandronate IV Q4W (43) |
−0.3585 (0.4260) |
−0.2832 (0.3916) |
−0.12 | – |
| Rosen 2001 (Rosen et al., 2001) | Zoledronate 4 mg IV Q3/4W (563) |
Pamidronate 90 mg IV Q3/4W (556) |
−0.0834 (0.0887) |
−0.0464 (0.0659) |
−0.3112 | – |
| Rosen 2003 (Rosen et al., 2003) |
Zoledronate 4 mg IV Q3W (254) |
Placebo IV Q4W (247) | −0.3106 (0.1402) |
−0.2133 (0.1039) |
NR | −0.9029 (week 36) |
| Saad 2002 (Saad et al., 2002) | Zoledronate 4 mg IV Q3W (214) |
Placebo IV Q3W (208) | −0.4050 (0.1497) |
−0.2876 (0.1244) |
−1.2448 | – |
| Stopeck 2010 (Stopeck et al., 2010) | Denosumab 120 mg SC Q4W (1026) |
Zoledronate 4 mg IV Q4W (1020) |
−0.1977 (0.0769) |
−0.1722 (0.0625) |
−0.43 | – |
| Theriault 1999 (Theriault et al., 1999) |
Pamidronate 90 mg IV Q4W (182) |
Placebo IV Q4W (189) | NR | −0.1815 (0.0830) |
NR | −0.3207 (week 96) |
| Zhao 2011 (Zhao et al., 2011) | Zoledronate 4 mg IV Q3W (30) |
Placebo IV Q3W (29) | NR | −0.0339 (0.6574) |
−1.2354 | – |
IV, intravenous; NR, not reported; Q3W, every 3 weeks; SC, subcutaneous; SE, standard error.